Get the Stockscreener App
15.30
0.40%
0.17
Relay Therapeutics Inc stock is traded at $15.30, with a volume of 251.02K.
It is up +0.40% in the last 24 hours and up +58.23% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
See More
Previous Close:
$15.13
Open:
$14.86
24h Volume:
251.02K
Relative Volume:
0.09
Market Cap:
$2.73B
Revenue:
$15.36M
Net Income/Loss:
$-276.48M
P/E Ratio:
-9.486
EPS:
-1.6129
Net Cash Flow:
$-235.87M
1W Performance:
-7.38%
1M Performance:
+58.23%
6M Performance:
+105.83%
1Y Performance:
+374.69%
1-Day Range:
$14.84
$15.29
1-Week Range:
$14.68
$17.15
52-Week Range:
$2.6701
$17.32
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
15.29 | 2.70B | 15.36M | -276.48M | -235.87M | -1.6129 |
VRTX
Vertex Pharmaceuticals Inc
|
432.58 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.65 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
789.47 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.83 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
303.28 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Breast cancer combo posts 44% response in pretreated patients - Stock Titan
Relay Therapeutics Announces Clinical Data for Zovegalisib - GlobeNewswire
Relay Therapeutics (RLAY) surges 16.4%: Is this an indication of further gains? - MSN
Industry Analysts Just Upgraded Their Relay Therapeutics, Inc. (NASDAQ:RLAY) Revenue Forecasts By 57% - Moomoo
RLAY SEC FilingsRelay Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
RLAY PE Ratio & Valuation, Is RLAY Overvalued - Intellectia AI
Relay Therapeutics (RLAY) Stock: Is It a Good Buy | Q4 2025: EPS Beats ForecastsReal-time Trade Ideas - UBND thành phố Hải Phòng
Is Relay Therapeutics (RLAY) stock strengthening its trend | Q4 2025: EPS Beats ForecastsCommunity Buy Alerts - Cổng thông tin điện tử Tỉnh Sơn La
JonesResearch Initiates Coverage of Relay Therapeutics with Hold Rating - HarianBasis.co
Relay Therapeutics (RLAY) climbs 16% ahead of cancer treatment update - MSN
Is Relay Therapeutics (RLAY) stock gaining momentum (Mini Selloff) 2026-04-20Fast Moving Stocks - Xã Vĩnh Công
JonesResearch Initiates Coverage of Relay Therapeutics (RLAY) With a Hold Rating - Insider Monkey
Relay Therapeutics (RLAY) Stock: Stability Assessment (Buying Pressure) 2026-04-18Intraday Trading - Cổng thông tin điện tử Tỉnh Sơn La
5 Best Low Priced Biotech Stocks to Invest In - Insider Monkey
Tudor Investment Corp ET AL Acquires New Shares in Relay Therapeutics, Inc. $RLAY - MarketBeat
PERCEPTIVE ADVISORS LLC Significantly Reduces Stake in Relay The - GuruFocus
[PRE 14A] Relay Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan
Jones Trading initiates coverage of Relay Therapeutics (RLAY) with hold recommendation - MSN
Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year HighShould You Buy? - MarketBeat
RLAY Initiated Coverage by Jones Trading -- Rating Set to Hold - GuruFocus
JonesTrading Initiates Coverage on Relay Therapeutics (NASDAQ:RLAY) - MarketBeat
Perceptive Fund (RLAY) reports 9.99% ownership — 438,471 shares - Stock Titan
Will Relay Therapeutics (RLAY) Stock Recover Soon | Price at $15.21, Up 1.81%Price Target - UBND thành phố Hải Phòng
Relay Therapeutics CFO Sells $27,000 in Stock - National Today
Relay Therapeutics CFO Sells $27,000 in Shares - National Today
Relay Therapeutics stock hits 52-week high at 14.98 USD By Investing.com - Investing.com Canada
Relay Therapeutics Hits New 52-Week High After Analyst Upgrade - National Today
Earnings Recap: Will Relay Therapeutics Inc benefit from green energy policies2026 Action & Reliable Entry Point Alerts - baoquankhu1.vn
Catinazzo, Relay Therapeutics CFO, sells $257k in RLAY stock By Investing.com - Investing.com Australia
Catinazzo, Relay Therapeutics CFO, sells $257k in RLAY stock - Investing.com
Thomas Catinazzo Sells 1,800 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock - MarketBeat
Relay Therapeutics (NASDAQ: RLAY) CFO logs 19,517-share sale under 10b5-1 plan - Stock Titan
Rally Mode: Will Relay Therapeutics Inc benefit from government policyRate Cut & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Relay Therapeutics stock hits 52-week high at 14.98 USD - Investing.com
Relay Therapeutics (NASDAQ:RLAY) CFO Sells $230,498.17 in Stock - MarketBeat
Barclays Raises Price Target for Relay Therapeutics (RLAY) to $2 - GuruFocus
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relay Therapeutics Inc Stock (RLAY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Catinazzo Thomas | Chief Financial Officer |
Apr 07 '26 |
Sale |
13.01 |
17,717 |
230,498 |
213,867 |
| Catinazzo Thomas | Chief Financial Officer |
Apr 09 '26 |
Sale |
15.00 |
1,800 |
27,000 |
213,867 |
| Catinazzo Thomas | Chief Financial Officer |
Mar 09 '26 |
Sale |
10.06 |
17,717 |
178,233 |
231,584 |
0.03%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):